Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Preclinical Models for Assessing Off-Tumor Toxicity and Cytokine Release Syndrome of CAR-T Cell Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Models for Assessing Off-Tumor Toxicity and Cytokine Release Syndrome of CAR-T Cell Therapies

Preclinical Models for CAR-T Cell Therapy Safety Assessment

CELL & GENE | RNA | BIOLOGICS

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A science-based preclinical strategy for Chimeric Antigen Receptor (CAR)-T cell therapies must characterize the primary safety liabilities: on-target, off-tumor toxicity and Cytokine Release Syndrome (CRS). The selection of appropriate in vivo models and the design of IND-enabling toxicology studies are tailored to the specific CAR construct and target antigen. This approach integrates foundational expertise in T-cell immunology with access to specialized nonhuman primate (NHP) models to minimize clinical risk and support regulatory submissions to the FDA and European authorities.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

Frequently Asked Questions

    What is the primary objective of a CAR-T preclinical safety program?

    The objective is to characterize the potential for on-target, off-tumor toxicity and cytokine-mediated toxicities. This involves designing studies that can predict the dose-dependent safety profile and establish a safe starting dose for first-in-human trials.

    Why is a standard toxicology template insufficient for CAR-T therapies?

    CAR-T therapies are living products with complex, dynamic biology. A one-size-fits-all preclinical testing template does not exist. A tailored strategy is required, accounting for the CAR construct, target antigen expression profile, and the specific cell phenotype (e.g., autologous vs. allogeneic CAR-T, CAR-NK).

    Which in vivo models are most relevant for assessing CAR-T safety?

    Model selection depends on the scientific question. Syngeneic tumor models in immunocompetent systems can assess on-target activity and certain toxicities. For evaluating human CAR-T cells, immunodeficient systems engrafted with human tumors are common. For comprehensive safety assessment, particularly for targets with human-NHP cross-reactivity, nonhuman primate models provide highly predictive data.

    How does Franklin Biolabs support submissions in Europe?

    Our study designs and reports are structured to support both FDA IND submissions and Investigational Medicinal Product Dossier (IMPD) submissions for European authorities. We align our programs with the regulatory expectations for Advanced Therapy Medicinal Products (ATMPs).

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

The Challenge of Predicting CAR-T Toxicities

Assessing the safety profile of a CAR-T cell therapy requires a preclinical program that addresses its unique biological activity. The two principal risks are on-target, off-tumor toxicity, where the CAR-T cells attack healthy tissues expressing the target antigen, and Cytokine Release Syndrome, a systemic inflammatory response. Predicting these events demands a deep understanding of T-cell activation and persistence.

Our background in characterizing vector-induced T-cell activation (PMID: 15823604, 24829340) provides the immunological foundation for designing these complex safety studies. The ability to profile T-cell responses is directly applicable to monitoring the kinetics of CAR-T cell expansion and cytokine production that drive both efficacy and potential toxicity.

A Tailored Preclinical Strategy for Somatic Cell Therapies

A data-driven preclinical strategy is designed specifically for the asset modality and target indication. Franklin Biolabs operates within a >100,000 sq ft facility to execute these customized programs, which typically progress candidates to IND within an 18-24 month timeline.

Our approach for CAR-T programs includes:

  • Target Antigen Expression Profiling: Comprehensive histology and protein analysis to map the expression of the target antigen across a full panel of human and animal tissues. This informs the assessment of potential on-target, off-tumor liabilities.

  • In Vivo Model Selection: Use of appropriate immunocompromised rodent models for initial efficacy and tolerability assessments. For definitive IND-enabling toxicology studies, we leverage NHP models where the target antigen shows relevant cross-reactivity.

  • Phase-Appropriate Bioanalysis: Development and qualification of assays under GxP conditions to monitor CAR-T cell persistence, expansion, and key cytokine biomarkers (e.g., IL-6, IFN-γ) associated with CRS.

Since its launch in 2024, the scientific leadership team at Franklin Biolabs maintains a 100% successful IND submission rate dating back to 2019.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Animal Welfare and Model Selection

The ethical and scientific integrity of our in vivo programs is a core principle. All studies are conducted in compliance with AAALAC and USDA guidelines, strictly adhering to the 3Rs principle (Replacement, Reduction, and Refinement) of animal welfare. For NHP studies, we implement enhanced housing conditions and cognitive enrichment programs throughout the in-life phase to ensure the highest standards of care.

Technical Visualization: Dual-Pathway Safety Assessment for CAR-T Therapies

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities